European Archives - Page 1083 of 1200 - European Medical Journal

EMJ

Helsinn Supports the Development of NCCN Guidelines for Patients® on Nausea and Vomiting, with a Sponsorship Grant

Lugano, Switzerland, April 11, 2016: Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, announces that it is supporting…

EMJ

Heine H. Hansen Award Goes to Suresh Senan

Geneva, Switzerland, 11 April: The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC)…

EMJ

Current Diabetes Treatments Are Not a Patch on This: The Smart Cell Patch

SMART insulin technologies, in the form of the newly developed ‘smart cell patch’ could represent a future solution for the treatment of patients with…

EMJ

Long-Term Diabetes Reversal: More Than Just a Magic Trick

REVERSIBLE! A concept that may seem unimaginable to patients with diabetes, has now been demonstrated by a study from Newcastle University.

EMJ

Introducing the European Medical Journal 1.2

United Kingdom, April 05, 2016: The second edition of our new eJournal series, the European Medical Journal, EMJ 1.2, is available now…

How I Treat: Lung Cancer

Lung cancer is the most common cancer and the leading cause of cancer-related deaths worldwide, accounting for about 1.8 million new diagnoses with…

Big Data and Cardiology: Time for Mass Analytics?

The dawn of the millennium coupled with developments in technology has led to the computerisation of information previously collected with paper and…

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

The American Society of Clinical Oncology’s 2016 Gastrointestinal Cancer Symposium (ASCO-GI), held in San Francisco, California, USA, provided a forum…

Editor’s Pick: Urgent Start Peritoneal Dialysis: A Viable Option for Acute and Chronic Kidney Failure

Peritoneal dialysis (PD) may be a feasible, safe, and complementary alternative to haemodialysis, not only in the chronic setting, but also in the acute.

Patient Insight and Treatment Expectations in Erectile Dysfunction

In the literature, a strong preference towards pharmacological management with oral phosphodiesterase type 5 (PDE5) inhibitors has been demonstrated…